Navigation Links
Scientists design new drug type to kill lymphoma cells
Date:5/10/2010

Three researchers who are recipients of a collaborative grant from the Samuel Waxman Cancer Research Foundation have developed a new type of drug designed to kill non-Hodgkin lymphoma tumor cells. The breakthrough could lead to potential non-toxic therapies for cancer patients. The Foundation-funded investigators include Ari Melnick, M.D., of Weill Cornell Medical College, Alexander MacKerell, Ph.D., of the University of Maryland and Gilbert Priv, Ph.D., of the University of Toronto. The researchers, who published their findings in the April issue of Cancer Cell, have identified a drug that targets an oncogene known as BCL6.

BCL6 functions as a master regulatory protein. "It's a protein that controls the production of thousands of other genes," said Dr. Melnick, an associate professor of medicine at Weill Cornell Medical College in New York City. "Because of that, it has a very profound impact on cells and is required for lymphoma cells to survive and multiply."

BCL6 causes the majority of diffuse large B cell lymphomas, the most common form of non-Hodgkin lymphoma. Currently, about 60 percent of diffuse large B cell lymphomas can be cured with chemo-immunotherapy, said Dr. Melnick. "The hope is that we can improve that to a higher percent, and in the long term reduce the need for chemotherapy," he added.

Traditional cancer drugs target enzymes, which have small pockets on their surfaces that can be blocked with molecules. Until now, pharmaceutical companies have been reluctant to create drugs that target a protein like BCL6 because they function through a different mechanism involving interactions with cofactor proteins involving extensive protein surfaces. "And because the real estate covered by these interactions is so large, the drug companies have viewed these as being not druggable targets," said Dr. Melnick.

He and his colleagues were able to identify a "hot spot" on BLC6 that they predicted would play a critical rol
'/>"/>

Contact: Jenny Song
jsong@waxmancancer.org
212-348-0136
Samuel Waxman Cancer Research Foundation
Source:Eurekalert

Page: 1 2

Related biology news :

1. UK scientists working to help cut ID theft
2. Scientists show that mitochondrial DNA variants are linked to risk factors for type 2 diabetes
3. Comet probes reveal evidence of origin of life, scientists claim
4. Scientists link fragile X tremor/ataxia syndrome to binding protein in RNA
5. Male elephants get photo IDs from scientists
6. Scientists retrace evolution with first atomic structure of an ancient protein
7. Muscle mass: Scientists identify novel mode of transcriptional regulation during myogenesis
8. Carnegie Mellon scientists develop nanogels that enable controlled delivery of carbohydrate drugs
9. Clemson scientists shed light on molecules in living cells
10. Scientists tackle mystery mountain illness
11. T. rex quicker than Becks, say scientists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/5/2015)... Calif. , Aug. 5, 2015 The ... continuous growth in applications, penetration into newer sectors, and ... year. The global biosensors space has seen the entry ... the market so far. (Photo - ... & Sullivan, Analysis of the Global Biosensors Market ...
(Date:8/3/2015)... 3, 2015 Synaptics, Inc. (Nasdaq: SYNA ... announced that members of the executive management team will ... Global Technology Leadership Forum on Tuesday, August 11, 2015 ... held at the Sonnenalp Resort in Vail, ... include forward-looking information. An audio webcast of the event ...
(Date:7/31/2015)... SHENZHEN, China , 31 de julho de 2015 ... Genômica (ICG-10, www.icg-10.org ) será realizada pela BGI de ... China . A conferência está ... inauguração em 2006, a ICG se tornou uma das ... e um dos encontros científicos mais dinâmicos, entusiastas e ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... Office has granted an exclusive license of a novel ... Inc., which plans to initiate early-stage human clinical trials ... Gary Landreth, PhD, the Riuko and Archie G. Co ... PhD, co-founded ReXceptor after discovering that bexarotene (a medication ...
... and Oxford, UK Cancer cells are a problem for ... blithely metastasize to set up shop in places where they ... this way is a tumor suppressor named p53. This protein ... those that are damaged beyond repair. Not surprisingly, p53,s critical ...
... across the UK has shown a grass hybrid species ... The BBSRC-funded scientists, from Rothamsted Research, the James Hutton ... at Aberystwyth University, Lancaster University and the University of ... perennial ryegrass ( Lolium perenne ) with a closely ...
Cached Biology News:Research spinoff ReXceptor gets license for Alzheimer's treatment 2Reviving a foe of cancer 2New grass hybrid could help reduce the likelihood of flooding 2
(Date:8/28/2015)... ... 28, 2015 , ... Proove Biosciences , a commercial ... Spine Intervention Society’ s 23rd Annual Scientific Meeting (ASM). The ASM event ... focus on evidence-based research and clinical application, the event gathered industry thought leaders ...
(Date:8/28/2015)... ... August 28, 2015 , ... Riordan-McKenna Institute ... DO, announced today that the use of sterile, dehydrated amniotic tissue AlphaPATCH™ developed ... an otherwise non-healing surgical knee wound. , The case involved a 78-year-old male, ...
(Date:8/27/2015)... ... , ... Capital Edge Consulting , a nationwide consulting firm that specializes ... ranking as one of the top 5000 companies listed on the 2015 Inc. ... , “It is truly an honor to be recognized as one of America’s fastest ...
(Date:8/27/2015)... 2015 The National Necrotizing Fasciitis Foundation ... saved by doctors at Vanderbilt University Hospital in ... Pharmaceuticals and Dr. John Crew , director of ... Medical Center in Daly City, CA. ... approach, pioneered by Dr. Crew, that had previously saved ...
Breaking Biology Technology:Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 2Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 3Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 4Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 2Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 3Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 4Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3
... , , , , ... Imagenetix, Inc. (OTC Bulletin Board: IAGX) announced today results for its first fiscal ... from the $1,394,000 reported for the same period last year. , ... compared to a net profit for the same period of the prior fiscal year ...
... , , , LEXINGTON, ... for Genome Resources (NCGR) has selected febit,s DNA-capture method, HybSelect(TM), ... of the most devastating childhood diseases with the ultimate goal ... genetic diseases in prospective parents. , , ...
... and VANCOUVER, Aug. 10 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, ... that the United States Patent and Trademark Office ... entitled "Chemo-and Radiation-sensitization of Cancer by Antisense TRPM-2 ... cancer drug candidate, OGX-011, to treat certain cancers. ...
Cached Biology Technology:Imagenetix, Inc. Reports First Quarter 2010 Results 2Imagenetix, Inc. Reports First Quarter 2010 Results 3Imagenetix, Inc. Reports First Quarter 2010 Results 4Imagenetix, Inc. Reports First Quarter 2010 Results 5The National Center for Genome Resources Studies Childhood Diseases Using febit's DNA Capture Method 2The National Center for Genome Resources Studies Childhood Diseases Using febit's DNA Capture Method 3OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011 2OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011 3